Ainos, Inc.
AIMDAinos, Inc. is a dual-platform biotechnology company specializing in artificial intelligence-based scent digitization and immune therapeutics.
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
Ainos, Inc. is a dual-platform biotechnology company specializing in artificial intelligence-based scent digitization and immune therapeutics. The company's core value proposition lies in its proprietary AI Nose technology, which translates volatile organic compounds into machine-readable data for industrial and healthcare applications, alongside its VELDONA low-dose oral interferon platform for treating rare and autoimmune diseases.
Ainos is an early-stage innovator in the emerging 'SmellTech' field, leveraging a capital-efficient R&D hub in Taiwan to bridge the gap between AI sensing and traditional biotechnology.
FAQ
- What is Ainos, Inc.'s market cap?
- Ainos, Inc. (AIMD) has a market capitalization of $4.4M and trades on NASDAQ.
- Who are Ainos, Inc.'s competitors?
- Ainos, Inc.'s key competitors include Honeywell International Inc., Shuttle Pharmaceuticals Holdings, Inc. Common Stock, Fusemachines Inc. Common stock, and others. These companies compete in similar markets and product categories.
- Who does Ainos, Inc. partner with?
- Ainos, Inc.'s notable partners include Inabata & Co. Ltd., Topco Scientific Co., Ltd., Solomon Technology Corporation, and others.
- What subsidiaries does Ainos, Inc. have?
- Ainos, Inc.'s subsidiaries include ScentAI Inc..
- Where is Ainos, Inc. headquartered?
- Ainos, Inc. is headquartered in United States of America and employs approximately 46 people. It has been publicly traded since 1996.